What is HC Wainwright’s Estimate for Immunic Q1 Earnings?

Immunic, Inc. (NASDAQ:IMUX) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Immunic in a note issued to investors on Tuesday, April 15th. HC Wainwright analyst M. Caufield expects that the company will earn ($0.26) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunic’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS and Q4 2025 earnings at ($0.18) EPS.

IMUX has been the subject of several other reports. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. William Blair assumed coverage on shares of Immunic in a research report on Tuesday, March 25th. They issued an “outperform” rating for the company. Finally, D. Boral Capital reissued a “buy” rating and set a $17.00 target price on shares of Immunic in a research note on Thursday, April 10th. One research analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $13.20.

Immunic Price Performance

Shares of IMUX opened at $0.99 on Wednesday. The firm has a market capitalization of $89.07 million, a PE ratio of -0.80 and a beta of 1.91. The company’s 50-day moving average is $1.08 and its 200-day moving average is $1.15. Immunic has a fifty-two week low of $0.83 and a fifty-two week high of $2.11.

Hedge Funds Weigh In On Immunic

Several institutional investors and hedge funds have recently made changes to their positions in the business. Invesco Ltd. bought a new stake in Immunic during the 4th quarter valued at $37,000. Virtu Financial LLC purchased a new stake in shares of Immunic during the third quarter worth about $50,000. HB Wealth Management LLC purchased a new position in Immunic during the 4th quarter valued at about $81,000. Barclays PLC purchased a new stake in Immunic in the fourth quarter worth $84,000. Finally, Jane Street Group LLC boosted its holdings in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after acquiring an additional 38,553 shares in the last quarter. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.